Question 1

What is Process Characterization (PC) and Process Validation (PV) for lentiviral vectors, and why is it important?

Accepted Answer

Process Characterization (PC) and Process Validation (PV) are important development and regulatory activities that demonstrate a lentiviral vector manufacturing process is well understood, controlled, and capable of consistently producing high-quality products. These steps are essential for supporting Biologics License Application (BLA) submissions and commercial manufacturing readiness.

Question 2

What Process Characterization services does ProBio offer?

Accepted Answer

ProBio provides comprehensive Process Characterization services, including risk assessments, scale-down model development, Design of Experiments (DoE), and process characterization studies. These steps help identify critical process parameters (CPPs) and establish a deeper understanding of process performance.

Question 3

What Process Validation services are included in ProBio's LVV platform?

Accepted Answer

ProBio supports the full range of Process Validation activities, including validation plan development, risk assessments, manufacturing readiness preparation, Process Performance Qualification (PPQ), and supporting validation studies required for commercial manufacturing and BLA filing.

Question 4

How do scale-down models benefit lentiviral vector process development?

Accepted Answer

Scale-down models replicate commercial manufacturing conditions at a smaller scale, allowing efficient evaluation of process parameters, risk mitigation strategies, and process optimization before expensive GMP validation runs are performed.

Question 5

Can ProBio support both clinical and commercial lentiviral vector programs?

Accepted Answer

Yes. ProBio provides integrated lentiviral vector CDMO services covering process development, GMP manufacturing, Process Characterization, Process Validation, and commercial manufacturing support, enabling a seamless path from clinical development to product launch.

Question 6

How can PC/PV studies help reduce manufacturing risk? How does ProBio support?

Accepted Answer

PC/PV studies identify critical quality attributes (CQAs), critical process parameters (CPPs), and potential sources of variability. ProBio combines cGMP-compliant facilities, global regulatory expertise, extensive LVV manufacturing experience, and an integrated CDMO platform to enable efficient execution of PC/PV studies while helping sponsors advance toward BLA approval and commercial launch.

Lentiviral Vector PC/PV

Accelerate Your Pathway to Commercialization

Proven Experience

Streamlined Development

Global Compliance Confidence

BLA Solution for Cell Therapy Products

LVV PC/PV Workflow

Resources

From DNA to Therapy

Viral Vector GMP Manufacturing

ProBio CGT GMP Facilities

ProBio Hopewell Accelerating Transformative Medicines

ProBio and CuroCell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

ProBio CDMO Expands Viral Vector Development Capabilities at US site with New Packaging Test Platform

Discuss Your BLA Readiness Strategy

Related Services

LVV Development Services

LVV Plasmid Services

LVV Plasmid BLA PC / PV

CAR-T Therapy Discovery Service

Plasmid DNA solutions

LVV Drug Product IND-enabling CMC

Frequently Asked Questions